News
RNAC
7.41
-2.76%
-0.21
Weekly Report: what happened at RNAC last week (0914-0918)?
Weekly Report · 5d ago
Weekly Report: what happened at RNAC last week (0907-0911)?
Weekly Report · 09/14 09:19
Weekly Report: what happened at RNAC last week (0831-0904)?
Weekly Report · 09/07 09:18
Cartesian Therapeutics to Participate in Upcoming Investor Conferences
Barchart · 09/03 06:00
Weekly Report: what happened at RNAC last week (0824-0828)?
Weekly Report · 08/31 09:20
Weekly Report: what happened at RNAC last week (0817-0821)?
Weekly Report · 08/24 09:20
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 08/18 12:50
Cartesian Therapeutics Price Target Maintained With a $38.00/Share by Wedbush
Dow Jones · 08/18 12:45
Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target
Benzinga · 08/18 12:34
Weekly Report: what happened at RNAC last week (0810-0814)?
Weekly Report · 08/17 09:20
Adicet Bio: A Cheap Gamma Delta T-Cell Play
Seeking Alpha · 08/14 17:18
Cartesian Therapeutics (RNAC) Gets a Buy from Mizuho Securities
TipRanks · 08/12 01:15
Weekly Report: what happened at RNAC last week (0803-0807)?
Weekly Report · 08/10 09:19
Cantor Fitzgerald Keeps Their Buy Rating on Cartesian Therapeutics (RNAC)
TipRanks · 08/07 18:26
Cartesian Therapeutics: Late-Stage Descartes-08 De-Risking and 2027 Data Wave Underpin Van Buren’s Buy Rating
TipRanks · 08/07 08:08
Cartesian Therapeutics Announces New Employment Inducement Grants
Barchart · 08/07 06:00
Buy Rating Reiterated on Strong Cash Runway and Near‑Term Clinical Catalysts; $40 Price Target Maintained
TipRanks · 08/06 20:25
Cartesian Therapeutics Q2 EPS $0.46 Beats $(0.86) Estimate
Benzinga · 08/06 11:26
*Cartesian Therapeutics 2Q Research and Development Expenses $20.4M >RNAC
Dow Jones · 08/06 11:05
*Cartesian Therapeutics 2Q EPS 46c >RNAC
Dow Jones · 08/06 11:04
More
Webull provides a variety of real-time RNAC stock news. You can receive the latest news about Cartesian through multiple platforms. This information may help you make smarter investment decisions.
About RNAC
Cartesian Therapeutics, Inc. is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company’s lead asset, Descartes-08, is a chimeric antigen receptor T-cell therapy (CAR-T) entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-B-cell maturation antigen (BCMA) CAR-T being evaluated in a Phase 1 trial in patients with multiple myeloma. Descartes-08 is an autologous chimeric antigen receptor T-cell therapy product targeting B-cell maturation antigen in clinical development for generalized myasthenia gravis and systemic lupus erythematosus.